Pharmaceutical Executive: March 2026

A more thoughtful — and "unified" — model is emerging in consent-driven marketing in pharma.

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.

How organizations can gain an edge in the enterprise transformation to unified analytics that's accelerating across pharma.

Industry experts across the biotech sector discuss the latest trends impacting emerging biotech companies, including the challenges of early-stage biotech start-ups, AI integration across the sector, and the most recent innovations in drug discovery.

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics, factors that favor strategically driven growth pursuits ahead.

Leaning into a future downward pricing environment in pharma.

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Conversational AI is pushing engagers to prioritize clear, explainable guidance as patients and clinicians delegate understanding to chatbots.

From data risk to relationship equity, the need to rethink consent in life sciences marketing.

Most medical digital pilots are designed for success in controlled conditions.

Catalyst’s executive director of patient advocacy discusses the company’s new undergraduate program that provides participants with real-world experience in advocacy.